James Lennertz, Group VP and GM EUMEA for BioMarin, discusses the key highlights of the past few years for BioMarin, their unique positioning as a company offering innovative therapies for ultra-rare diseases, the main challenge he sees for BioMarin’s international operations, and his priorities for the next few years.
James, as Group VP and GM EUMEA for BioMarin, you have a very broad remit. Can you give us an overview of your responsibilities?
2016 and beyond will see a number of very exciting milestones for the company. Firstly, the group is celebrating our 20
th anniversary in 2017 after two decades of fantastic growth. The European organisation was founded in 2005 and our first product, Naglazyme, recently celebrated its tenth anniversary of being on the market, so it was doubly exciting for us here in Ireland.
"My core objective is to facilitate patient access to the innovative medicines that we provide."
